Answers are grounded in this paper and cite their sources.
Systematic review highlights venetoclax and rituximab effectiveness in relapse/refractory CLL treatment in Brazil, indicating strong options.
This NMA provides valuable evidence to support rational therapeutic choices for RR-CLL in Brazil, highlighting VenR and Bruton tyrosine kinase inhibitors as leading treatment options across diverse clinical scenarios.
No takes yet. Share an insight, caveat, or question.
Barros et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: